MedTech Trends in 2026
How to focus on what's behind all the noise
Every year, the industry publishes its “top trends” lists. Most people skim them, nod along, and go back to their Monday morning meeting and double-espresso.
As my readers explicitly asked me to write about trends, well … this year is different. The same topic getting flagged in multiple reports is no longer a trend, it is a signal.
Here’s what’s actually happening with this industry - and more importantly, what it means for you (as a CEO, Founder, start-up or professional).
1. The FDA is overwhelmed - launching into USA is slower now
The FDA went through a government shutdown. Senior reviewers, people with 20+ years of experience — were furloughed, which is more or less equal in impact with layoffs. Backlogs were building up, obviously, and when operations resumed, the agency shifted to “written response only” mode to manage the pile.
What does that mean in practice?
It means the informal coffee-style dialogue you used to have with FDA reviewers before a formal submission is gone - or at minimum, severely delayed. The collaborative back-and-forth that helped you fix problems early? You should expect less of it.
The FDA is also going through several transitions, which means that launching into USA is slower now. They are in the process of upgrading their internal tools (Elsa 4.0 - AI tool used by reviewers, investigators, and field staff across the agency). In parallel, they are building a platform - HALO (Harmonized AI & Lifecycle Operations for Data). If previously the reviewers could hardly identify gaps in 400 pages in PDF, it will become very easy to detect them in HALO, so pay attention.
How to save time: Audit your submissions with the same rigor you’d apply to a clinical study. Assume you will get written responses only. Design your dossier to be self-explanatory, clean, clear, because you may not get the chance to explain it verbally.
2. The portfolio breakup in large companies
Medtronic is spinning off its diabetes division. J&J is separating DePuy Synthes. BD is merging its biosciences unit with Waters Corp. Philips is selling Emergency Care. Siemens is exploring divesting its diagnostics arm.
This is not a coincidence. This is a structural general reset.
Large MedTech companies built themselves into sprawling portfolios over 20 years. For the Founders and mid-size companies, this is the opening you’ve been waiting for.
Newly independent divisions need new partners, new supply chains, new commercial relationships. They’re free to collaborate with companies that were previously off-limits because of parent company conflicts. Private equity is circling these assets, bundling them, and building focused portfolios.
What to do: Map which divested assets are adjacent to your space. Watch where PE money flows — that’s your signal about which assets are being positioned for growth. And if you’re a start-up, ask yourself: could a newly independent division become your distribution partner, acquirer, or co-development ally?
3. The workforce problem in MedTech is real
All the large MedTech companies consistently report difficulty attracting and keeping the tech talent they need, as you’ve probably seen in all the declarations. The issue is not with the talent or people, it's a value exchange problem — and most large companies do not want to admit that yet.
With the entire AI wave and tech being more and more present into healthcare, the demand is clear — software engineers, data scientists, AI specialists, cloud architects, cybersecurity experts. The problem? Google, Microsoft, and well-funded start-ups are offering more money, more flexibility, treating employees better, offering stocks or equity, etc.
What's less visible, but equally serious: experienced MedTech professionals (people with 15 to 20 years in the industry) are quietly exiting. Not into retirement, but into tech, energy, and automotive. Industries that pay differently, move faster, and treat expertise as a competitive asset.
We also need to address another layer, which is skills level & training of the professionals. Clinical and operational talent is also under severe pressure. Nearly 40% of today’s job skills may become outdated because of AI and automation — meaning the workforce you have today needs continuous upskilling just to stay relevant.
What to do: Compete on mission, complexity, and impact. A skilled engineer building a wound-care AI algorithm that improves patient outcomes has a story that no social media ad platform can match. Tell that story loudly. Build up-skilling programs, explore borderless hiring, partner with universities, and make your employer brand as strong as your product brand.
4. Surgical Robotics: the market is opening more
For years, Intuitive Surgical owned this space. Da Vinci was the only game in town for soft tissue robotics.
That era is ending.
Medtronic’s Hugo just got FDA clearance for urologic procedures. J&J’s OTTAVA just completed the clinical study 3 days ago. Smaller players — Moon Surgical, Distalmotion, CMR Surgical — are carving out niches with lighter, cheaper systems. India’s SS Innovations filed a 510(k) for a lower-cost robot. China’s MicroPort MedBot is scaling value-oriented systems globally.
Meanwhile, the space is expanding beyond traditional robotics. HistoSonics raised $250M for incisionless histotripsy. Petal Surgical emerged from stealth with over $25M in total funding to develop incisionless robotic surgery using proprietary acoustic liquefaction technology. The interventional playbook is being rewritten, from cutting to energy-based image-guided therapies.
The challenge that remains? Reimbursement. ROI is built on outcomes, efficiency, and service line strategy — not per-case premiums, and that will not change quickly.
What to do: If you’re building in this space, your story needs to be about outcomes and total cost of care, not just about the technology. And watch the Ambulatory Surgery Center’s channel closely. As capital burden models evolve, ASCs represent a massive untapped market for right-sized robotic systems.
5. Diagnostics and the Sleep Market
Diagnostics — Point-of-Care testing is growing at 6-7% annually, expanding from emergency departments into pharmacies, clinics, and homes. The liquid biopsy market is a $7-8 billion global opportunity, growing fast (non-invasive, repeatable, biomarker-rich). All of these tests are becoming the standard of care, not speciality tools.
Sleep — Clinicians have known for decades that sleep is as fundamental as nutrition and exercise. The data just wasn’t there. Now it is. Wearables and AI are generating unprecedented volumes of sleep data. Beacon Biosignals raised $86M. Eight Sleep raised $100M Series D. Investors are paying attention.
Both of these spaces share a common thread: they’re moving healthcare from reactive to proactive. From treating disease to detecting and preventing it.
That shift from hospital to home and from treatment to prevention is the single biggest structural change happening in healthcare right now.
What to do: If your product or pipeline touches diagnostics, sleep, or remote monitoring, you’re in the right place at the right time. The question is execution. Can you build the evidence, achieve the integration, and tell the value story clearly enough to get reimbursed and adopted at scale?
6. Cybersecurity
In 2026, cybersecurity is a board-level issue. Ransomware attacks on hospitals are increasing globally. When a hospital’s systems go down, patient care is disrupted, medical errors increase, lives are at risk.
That’s not a data breach - it’s a patient safety event.
The EU Cybersecurity Reserve launched in 2026. HIPAA Security Rule enforcement is tightening in the US. And for MedTech companies specifically, cybersecurity certification is now a prerequisite for EHR integration — meaning it’s a market access issue, not just a compliance checkbox.
What to do: Treat cybersecurity the same way you treat clinical evidence — as a foundational requirement, not an afterthought. Assign ownership at the executive level, build it into your product design. Get certified early!
7. Health systems are broke — and that’s your problem too
Let’s talk about your customer’s reality for a second (or more seconds).
The hospitals and health systems you’re selling to are under massive financial pressure. That matters to you directly, because a financially stressed hospital buys differently. Procurement cycles get longer, value justification requirements get harder and the “we love your technology” conversation stops translating into signed contracts.
But here’s the other side of it: health systems aren’t just cutting costs, they are also actively transforming their care model. Outpatient is growing, virtual care is expanding and remote monitoring is moving from pilot to standard. Deloitte’s data shows 64 % of health system executives expect AI-driven workflow automation to be their primary source of cost savings in 2026.
They’re not looking for a device. They’re looking for a solution that fits into a leaner, more distributed, more preventive model of care.
If your value story is still built around hospital throughput and inpatient workflow - you’re selling to a model that’s shrinking.
What to do: Reframe your value proposition around the care model your customers are building toward, not the one they’re currently running. Show ROI in terms of reduced length of stay, lower readmissions, staff time saved, and outpatient-compatible workflows. And if your product can move care from hospital to home — lead with that.
Healthcare is being fundamentally restructured.
The hospital at the center, treating disease after it happens, financed by volume » that model is breaking down under its own weight. What’s replacing it is distributed, data-driven, preventive and AI-enabled.
For MedTech companies, the opportunity is enormous. But the gap between companies that are building for this future and companies that are still operating by yesterday’s assumptions is widening fast.
The question isn’t whether you see the trends, it’s whether you’re controlling the signals and keep building for the future.
Hi, I’m Alina. I work with MedTech Founders and C-level executives on the things that make or break a company before it’s visible from the outside — strategy, brand positioning, regulatory readiness, investor narratives, and the messy gap between having a great idea and building a successful company.
If this resonates, let’s talk: Book a call / Send me a message